Procuring TB Medicines - PowerPoint PPT Presentation

1 / 46
About This Presentation
Title:

Procuring TB Medicines

Description:

Recognize characteristics of a good pharmaceutical procurement system ... Programs must follow recommendations to avoid development of resistance to 2nd ... – PowerPoint PPT presentation

Number of Views:68
Avg rating:3.0/5.0
Slides: 47
Provided by: Thomas609
Category:

less

Transcript and Presenter's Notes

Title: Procuring TB Medicines


1
Procuring TB Medicines
2
Unit Objectives
  • Recognize characteristics of a good
    pharmaceutical procurement system
  • Understand the importance of price comparison as
    an indicator of procurement efficiency
  • Understand the conditions and procedures required
    by GDF and GLC for procuring TB medicines

3
Unit Outline
  • Goals of effective procurement
  • Good Pharmaceutical Procurement Practice
  • Sources of TB Medicines
  • Procurement Methods
  • Tendering
  • Procurement from GDF and GLC
  • Activity

4
Pharmaceutical Management Cycle
5
TB Supplies and Medicines to Procure
  • Anti-bacterials
  • Medicines used for adverse reactions
  • Supplies for injectables such as syringes, IV
    administration sets
  • Reagents/standards for laboratory tests
  • Others

6
Goals of Effective Procurement
  • The correct medicines and supplies
  • Meeting required quality standards
  • In the correct quantities
  • Delivered in a timely manner
  • At the lowest possible purchase price

7
Good Procurement Practices (1)
  • Use generic name procure best quality product
  • Limit to tuberculosis essential medicines list
  • Purchase in Bulk
  • Setup formal supplier qualification and
    monitoring
  • Use competitive procurement methods
  • Order quantities based on reliable estimate of
    actual need

8
Good Procurement Practices (2)
  • Manage finances, pay on time to avoid penalties
  • Follow transparency procedures, good
    documentation
  • Separate key functions
  • Establish product quality assurance program
  • Conduct annual audit, publish results
  • Report regularly on performance
  • Plan for procurement

9
Procurement Methods (1)
  • Open tender
  • Restricted tender
  • Competitive negotiation
  • Direct procurement

10
Procurement Methods (2)
  • Competitive
  • Open tendertender open to all bidders whether
    national or international
  • Restricted tendertender open only to suppliers
    prequalified by the procurement department
  • Competitive negotiationcontacting a few
    suppliers who are potentially interested
  • Noncompetitive
  • Direct procurementdirect purchasing from a
    single supplier at a quoted price

11
Advantages of Competitive Procurement
  • Minimizes costs, especially when using
    competitive practices
  • Promotes high-quality products
  • Manufacturer follows GMPs (raw material,
    manufacturing/packaging processes, quality
    controlall compliant with WHO guidelines)
  • Ensures reliability
  • All quantities ordered are received
  • Deliveries are made within expected delivery
    period

12
Disadvantages of Direct Procurement
  • No competition for prices and services
  • Increases unit costs (exceptions apply)
  • Sole supplier increases risk of stock-outs
  • Natural catastrophes affect manufacturing sites
  • Raw material supplier unable to provide starting
    substances
  • Supplier gets bigger or better order from another
    client

13
When Is Direct Procurement Okay?
  • When market forces fail and TB program lacks
    procurement skills
  • Results
  • low demand for medicines, therefore few
    suppliers, no competitive procurement higher
    prices
  • Options
  • pooled procurement by organizations like GDF and
    GLC

14
Sources of TB Medicines
  • Global Drug Facility (GDF)
  • 1st line medicines at special prices
  • Governments and organizations can buy since 2002
  • Countries can apply to GDF for free grants
  • Green Light Committee (GLC)
  • 2nd line medicines at special prices
  • International agencies
  • UNICEF
  • PAHO
  • Nonprofit suppliers (IDA and others)
  • Donors

15
Donations--cautions
  • Should be intended to assist the recipient
    country
  • Should respect authorities and support existing
    government policies
  • Should not be of lesser quality
  • Should be preceded by effective communication
    between donor and recipient

SourceWHO Guidelines for Drug Donations
16
Comparing Prices of GDF and Other Suppliersper
regimen
  • To treat one Category I or III patient of medium
    weight (40-54 kg)
  • GDF US 10.21 (CIF)
  • Other suppliers US 30 - 50 (CIF)

17
GDF prices vs. International and Kenya --per
medicine
RHZE
Price reductions--about 30 vs.
International--0-45 vs. Kenya
RH 150100
E400
Kenya GDF MSH Intl Price Guide
EH 400150
H300
Government of Kenya procurement before
GDF RHZE 15075400275 cost per
1,000 tablets
18
Comparing Prices of GLC and Other Suppliers
Source Science vol. 293, August 2001
19
Tendering for TB medicines
20
Components of Tender Documents
  • Invitation to bid
  • General conditions of pending contract
  • definitions, application, country of origin,
    patent rights, inspections and tests, packing,
    delivery, payment, price
  • General technical specifications
  • product quality and package specifications,
    product information, expiration date, recalls and
    disposal, labeling instructions, unique
    identifiers, qualifications of manufacturer

21
Useful Documents
  • Review Annex 3.1 Sample Supplier Registration
    Form
  • Review Annex 3.2 Example of Standard Bidding
    Document and Annex 3.3 Standard Bidding
    Documents for Procuring Tuberculosis Drugs (MSH
    Template)

22
Procuring medicines through the Global TB Drug
Facility (GDF) for 1st line medicines
23
GDF
  • Housed in WHO and managed by Stop TB partnership
    secretariat.
  • Aims to supply quality assured, affordable drugs
    in a timely manner, for 10 million people with TB
    by 2005
  • A bundled facility not a procurement agent

24
GDFA Novel Approach to.
  • Accelerate DOTS expansion
  • Meet the following needs
  • More resources for TB drugs
  • High quality TB drugs
  • Efficient procurement systems
  • Standardized guidelines and products
  • Monitoring of drug use
  • Technical assistance in drug management

25
What GDF Provides
  • Grants of first line drugssupports DOTS
    expansion
  • Direct procurement mechanismcountry buys drugs
  • Web-based toolplace orders, track shipments
  • Pre-qualified list of TB manufacturers
  • Standardized products and user-friendly packaging
  • Ongoing technical support, annual monitoring
    mission
  • Support for in-country drug management
  • Diagnostics and childrens dosages

26
Procuring from GDF--benefits
  • Competitive prices for TB products resulting in
    considerable savings.
  • Strong quality control of TB drugs
  • Variety of packages
  • Loose and blisters, FDCs, patient kits,
    diagnostics, childrens dosages, AD syringes
  • Services of experienced, reliable procurement
    agent
  • Relatively rapid lead time for delivery of TB
    drugs

27
Procuring from GDF-eligibility
  • Countries routinely implementing DOTS in 90 or
    more of the population
  • Organisations/agencies Donors committed to DOTS
    (as determined by the WHO DOTS Expansion Working
    Group of Stop TB)
  • Potential, but not yet pre-qualified clients may
    be able to use a special Approval to Buy
    process
  • More information at http//stoptb.unwebbuy.org/
    see visitor login

28
Procuring medicines through the Green Light
Committee (GLC) for MDR-TB
  • Statement
  • The Who/Stop TB working group identified access
    to second-line medicines as a major obstacle in
    implementing DOTS-Plus projects

29
Green Light Committee
  • Technical panel of the Stop TB/WHO working group
    on DOTS-Plus for MDR-TB
  • Members
  • WHO, CDC, IUATLD, NTP Estonia and Latvia,
    Harvard Medical School, MCA
  • Functions
  • Reviews projects and advises WHO/DOTS-Plus on
    which projects should benefit from specially
    priced quality-assured medicines

30
Green Light Committee
  • Functions (continued)
  • Arranges technical assistance through the GLC
    technical panel to TB programs wanting to
    establish a DOTS-Plus project
  • Monitors approved projects, providing for
    technical assistance as needed
  • Collects global evidence for developing policy in
    controlling MDR-TB

31
GLC Secretariat
  • Located in the Stop TB department at WHO
  • Currently has two staff members
  • Receives applications from TB programs wanting to
    implement a DOTS-Plus project
  • Carries out recommendations after the GLC
    technical panel has reviewed the applications
  • Performs procurement activities for second-line
    drugs through its procurement agent

32
GLC Pre-application Phase (1)
  • Before applying to the GLC, the potential
    DOTS-Plus project should
  • Ensure that the DOTS strategy is in place and is
    functioning well
  • Secure government commitment for long-term
    investment in staff and finances
  • Develop a coordinated project management
    planwritten procedures
  • Establish adequate laboratory services--with drug
    susceptibility testing (DST)

33
GLC Pre-application Phase (2)
  • Should (continued)
  • Devise a rational treatment strategybased on DST
  • Develop a specialized unit for managing MDR-TB
  • Develop a functioning information management
    system
  • Provide uninterrupted supply of quality medicines
  • Confirm registration of medicines in the country
  • Develop a port clearance plan when importing
    medicines

34
GLC Application Phase (1)
  • After the foundation of the program is in place,
    the applicant should
  • Prepare and submit an application to the GLC
    according to Instructions for Applying to the
    Green Light Committee for Access to Second-Line
    Anti-Tuberculosis Drugs, WHO/CDS/TB/2001.286
  • Respond to GLC comments, questions, requests for
    additional information or instructions resulting
    from the review of the application within the
    next three months

35
GLC Application Phase (2)
  • Facilitate a site visit, if requested by the GLC
  • Agree to specific terms and conditions as
    outlined in the Letter of Agreement with WHO

36
GLC Procurement
  • GLC works with a procurement agent
  • Current agent is IDA
  • (International Dispensary Association)
  • Not-for-profit company
  • Agreement signed between WHO and IDA in 2001 for
    3 years extended 1 year
  • IDA in charge of negotiation, procurement,
    quality assurance, and distribution
  • Adds 7 margin on purchase prices

37
GLC Quality Assurance
  • IDA uses good distribution practices (WHO)
  • IDA prequalifies manufacturers
  • Assesses quality assurance system
  • Audits the manufacturing plants
  • Performs laboratory analysis on batch samples
  • Sends information and documentation to facilitate
    registration of medicines in-country
  • WHO/EDM is currently pre-qualifying future GLC
    manufacturers

38
GLC Operational Process (1)
  • DOTS-Plus country projects approved by the GLC
    sign a contract with WHO
  • GLC secretariat introduces the approved project
    to the procurement agent by an official letter
  • Approved country project sends confirmation of
    order and payment to GLC secretariat and
    procurement agent
  • Medicines are delivered to the site designated by
    the DOTS-Plus country project

39
GLC Operational Process (2)
  • Takes four months from the time order is placed
    until delivered
  • No medicines are kept in stock by procurement
    agent
  • Manufacturers produce on demand
  • Current manufacturers are located in India, U.S.
    and Europe
  • Attention short shelf life for capreomycin,
    cycloserine and PAS

40
Mechanism for Applying and Buying
41
Operational Process (3)
  • Technical assistance from members of the Working
    Group is provided to projects as needed
  • Enrollment, treatment, and monitoring of patient
    cohort begins
  • Periodic data and reports are sent to WHO
  • Monitoring visits by GLC and consultants are
    conducted

42
Summarizing MDR-TB Treatment
  • Programs must follow recommendations to avoid
    development of resistance to 2nd-line TB
    medicines
  • From a public health point of view, it is better
    not to launch a DOTS-Plus project if appropriate
    conditions are not in place, such as
  • Ability to collect and analyze cohort data
  • Combined default and transfer rates under 10
  • Continual supply of 1st-line anti-TB medicines
  • Application of DOTS in 90 of cases

43
Advantages of a DOT-Plus Project
  • Access to quality-assured and low-cost medicines
  • Continuous supply of medicines
  • Technical assistance throughout life of project
  • External monitoring mechanism

44
Current Status of DOTS-Plus Projects
  • 34 projects have been approved by GLC technical
    review panel
  • In EMRO and surrounding regions 1 each in
    Egypt, Tunisia, Jordan, Syria and 2 in Uzbekistan
  • Other regions 7 in Russia 3 in Peru 2 in
    Honduras, 1 each in Estonia, Latvia, Kirghisie,
    Malawi, Philippines, Nepal, Moldova, Romania,
    Haiti, Mexico, Bolivia, Costa Rica, Nicaragua,
    Salvador, Ecuador, Dominican Republic

45
Comparing Suppliers Bids
46
Activity
  • Compare TB medicine prices from your country
  • With those of international sources
  • With those of other participants
  • Complete the form, Assessment of Procurement
    Practices in your country
  • Discuss
  • Do medicines need to be registered in your
    country before purchase?
  • Can your procurement unit buy directly from GDF
    or GLC without a tender?
  • Can your country afford to pay before the
    products are delivered and received?
Write a Comment
User Comments (0)
About PowerShow.com